Comparison of Clinical Efficacy and Safety between 70-150 µm and 100-300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma.
Jung Woo YiHyun Pyo HongMyung Sub KimByung Seok ShinHeon-Ju KwonByung Ik KimWon SohnPublished in: Life (Basel, Switzerland) (2022)
This study found no significant difference in tumor response between 70-150 μm and 100-300 μm DEB-TACE. Both groups showed favorable safety profiles, and the difference was not significant.
Keyphrases